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A Gabriella Wernicke*1, Adam P Dicker2, Michal Whiton2, Jana Ivanidze3, Terry Hyslop4, Elizabeth H Hammond5, 
Arie Perry6, David W Andrews7 and Lawrence Kenyon8
Abstract
Purpose: This study explores whether meningioma expresses epidermal growth factor receptor (EGFR) and 
determines if there is a correlation between the WHO grade of this tumor and the degree of EGFR expression.
Methods: Following institutional review board approval, 113 meningioma specimens from 89 patients were chosen. 
Of these, 85 were used for final analysis. After a blinded review, immunohistochemical stains for EGFR were performed. 
Staining intensity (SI) was scored on a scale 0-3 (from no staining to strong staining). Staining percentage of 
immunoreactive cells (SP) was scored 1-5 (from the least to the maximum percent of the specimen staining). 
Immunohistochemical score (IHS) was calculated as the product of SI and SP.
Results: Eighty-five samples of meningioma were classified in accordance with World Health Organization (WHO) 
criteria: benign 57/85 (67%), atypical 23/85 (27%), and malignant 5/85 (6%). The majority of samples demonstrated a 
moderate SI for EGFR. IHS for EGFR demonstrated a significant association between SI and histopathologic subtype. 
Also, there was a correlation between the SP and histopathologic subtype (p = 0.029). A significant association was 
determined when the benign and the atypical samples were compared to the malignant with respect to the SP (p = 
0.009). While there was a range of the IHS for the benign and the atypical histologic subtypes, malignant tumors 
exhibited the lowest score and were statistically different from the benign and the atypical specimens (p < 0.001).
Conclusions: To our knowledge, this represents the largest series of meningioma samples analyzed for EGFR 
expression reported in the literature. EGFR expression is greatest in benign meningiomas and may serve a potential 
target for therapeutic intervention with selective EGFR inhibitors.
Introduction
Meningiomas represent the second most common pri-
mary central nervous system tumors, with an annual inci-
dence in the U.S. of approximately 2.5 per 100,000 people
[1]. Primary therapy for meningioma is surgical interven-
tion, with the likelihood of recurrence inversely related to
the extent of resection [2]. Unfortunately, complete resec-
tion is not always possible because of the location of these
tumors near critical anatomical structures. The overall
recurrence rate of meningiomas has been reported to be
approximately 20%, with higher rates (30-40%) reported
in patients who undergo less than complete resection
(partial resection or biopsy) [3,4]. In addition, recurrence
rates are higher for the more aggressive histologic vari-
ants, with 5-year recurrence rates of 38% for atypical
meningiomas and 78% for malignant meningiomas [2,5].
The high recurrence rate in partially resected menin-
giomas has led to the use of additional therapy designed
to improve tumor control. Radiotherapy is frequently
administered after partial resection and has been shown
to decrease or delay recurrence. The control of recurrent
tumors continues to be a clinical challenge [6-8]. Cur-
rently, there are no pharmaceutical agents that are rou-
tinely used for adjuvant therapy. There is a considerable
interest in evaluating new molecular markers that may
also serve as potential therapeutic targets. Epidermal
growth factor (EGF) is a polypeptide hormone that acts
through activation of its cognate receptor (EGFR) and
stimulates proliferation of a wide variety of cells in vitro
and in vivo. The EGFR gene encodes a 170-kD membrane
spanning glycoprotein composed of an extracellular
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Page 2 of 7ligand binding domain, a transmembrane region, and a
cytoplasmic protein tyrosine kinase domain [9]. The
EGFR is thought to play an important role in the regula-
tion of cell division and tumor growth. In many cancers,
excessive EGFR overexpression has been shown to
stimulate angiogenesis, cell survival, and metastatic pro-
liferation.
A wide variety of normal and neoplastic tissues express
EGFR, and its overexpression has been detected in a
number of human tumors including breast [10], lung [11],
head and neck [12], glioblastoma multiforme [13,14], and
colorectal carcinomas [11,15], to name a few. Recently, an
interest emerged in assessing expression of EGFR in CNS
malignancies such as meningiomas, gliomas, etc [16,17].
In 1987, Weisman, et al. [18], characterized expression of
EGFR in meningiomas and suggested that EGFR is
involved in the proliferation and/or differentiation of
meningothelial cells. The present study represents the
largest series evaluating EGFR expression in menin-
giomas in the literature to date. The primary objectives of
the study are to determine if EGFR is expressed in menin-
gioma and whether there is a correlation between the
WHO tumor grade of this tumor and the degree of EGFR
expression.
Materials and methods
Case Selection
Following institutional review board approval, a comput-
erized search of the surgical pathology database of
Thomas Jefferson University Hospital (Philadelphia, PA)
and Washington University Hospital (St. Louis, MO) was
performed. A total of 113 meningioma specimens from
89 patients were identified between 1995 and 2001. Of
these, 85 were used from 85 patients for the final analysis
and chosen for further study based on adequacy of tissue,
tissue preservation, and unequivocal diagnostic features.
After review of the original hematoxylin and eosin
stained slides by a neuropathologist (L.C.K.), representa-
tive slides were chosen and immunohistochemical stains
for EGFR were performed on tissue sections from the
corresponding paraffin block.
Immunohistochemistry
Four-micron thick sections were cut from formalin fixed
tissue embedded in paraffin blocks and mounted onto
polylysine-coated slides. Tissue sections were subjected
to antigen retrieval by heating to 80-90 degrees Celsius
and stained for EGFR with commercially available anti-
sera (#M3563, clone H11, DAKO Corporation, Carpinte-
ria, CA). Detection was performed using a standard
biotin streptavidin detection system (DAKO, Carpinteria,
CA). All stains were performed on the DAKO
Autostainer.
Immunohistochemical Evaluation
Slides stained for EGFR were reviewed with the observers
blinded to classification of the tumor subtype. Sections of
colon cancer stained for EGFR were used as positive con-
trols. Staining intensity was scored on a scale of 0 to 3,
where 0 represents absent staining, 1-weak, 2-moderate,
and 3-strong staining of the tumor specimen (Figure 1).
The percentages of immunoreactive cells (staining per-
centage) were estimated by inspection and scored from 1
to 5, 1 (< 20% of the sample exhibiting staining); 2 (21-
40% of the sample exhibiting staining); 3 (41-60% of the
sample exhibiting staining); 4 (61-80% of the sample
exhibiting staining), and 5 (81-100% of the specimen
stained). An immunohistochemical score (IHS) was cal-
culated as the product of an estimate of the percentage of
immunoreactive cells (staining percentage (SP) score)
and the estimate of the staining intensity (staining inten-
sity (SI) score). When there was multifocal immunoreac-
tivity and a significant difference in staining intensities
between foci, a weighted average score was calculated.
The raw data were converted to the IHS by multiplying
the SI scores by SP scores.
Statistical Analysis
Prior to performing the analyses, the IHS of the speci-
mens with more than 1 slide cut from the specimen block
were averaged into one score, so that each of the eighty
five specimens was represented only once in the data
analysis. Analyses of association of pathology according
to WHO 2000 classification with SI, SP, and IHS were
carried out using exact Wilcoxon tests. In the case of IHS,
an exact Wilcoxon test was computed by Monte Carlo
methods, using 99% confidence and 10,000 Monte Carlo
simulations. All computations were completed by a statis-
Figure 1 Immunohistochemical staining intensity scores. A) Men-
ingiomas stained with anti-EGFR antisera showing negative staining. 
B) 1+ staining C) 2+ staining D) 3+ staining. Original magnification for 
all images was 40 ×.
Images are arranged as follows: Upper left (A), upper right (B), lower left 
(C), lower right (D).
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tion, Cambridge, MA).
Results
The tumors were originally classified according to the
WHO 2000 classification [19], however, no revision of
tumor grade is necessary when grading these tumors
using WHO 2007 classification [20]. The samples were
classified in accordance with pathologic grade and had
the following distribution: benign 57/85 (67%), atypical
23/85 (27%), and malignant 5/85 (6%). There were a total
of 24/85 (28%) of recurrent lesions: 11/57 (19%) of the
benign and 13/23 (57%) of the atypical lesions. The
patients were only represented once in this study; that is,
the same tumor was not examined for EGFR expression
upon recurrence. EGFR expression was detected in 86%
of all meningioma samples tested. There was a significant
association between intensity of EGFR staining and histo-
pathologic subtype based on the exact Wilcoxon test (p =
0.002) (Table 1). The majority of samples demonstrated a
moderate SI. Generally, the malignant meningiomas
exhibited very low scores of intensity of EGFR staining,
while benign and atypical samples demonstrated a higher
intensity of staining. Specifically, 80% (4/5) of malignant
samples had intensity scores of 0, and 20% (1/5) had
intensity scores of 1. Conversely, only 9% (3/23) of atypi-
cal and 13% (5/57) of benign tumor samples had 0 inten-
sity scores, whereas 23% (6/23) of atypical and 26% (13/
57) of benign meningiomas had intensity scores of 1. The
remaining proportions (61% (39/57) and 68% (14/23) of
benign and atypical, respectively) had SI of 2 and higher
(Table 2). Our data demonstrate that benign and atypical
meningiomas stain more intensely than malignant men-
ingiomas. In fact, when data from IHS for the benign and
the atypical histopathologic types were combined and
compared to the IHS for malignant meningiomas, we
found a statistically significant association (p < 0.001)
(Table 1).
There was also a significant association between per-
centage of tumor cell immunoreactivity or immunoreac-
tive cells (SP) and histopathologic subtype (p = 0.029)
(Table 1). As the percentages of SP were estimated by
inspection and scored from 1 to 5, 1 (< 20% of the sample
exhibiting staining); 2 (21-40% of the sample exhibiting
staining); 3 (41-60% of the sample exhibiting staining); 4
(61-80% of the sample exhibiting staining), and 5 (81-
100% of the specimen stained), we found that while the
benign and atypical meningiomas demonstrated interme-
diate to marked SP categories, all of the malignant men-
ingioma samples had low scores of SP for EGFR. To
illustrate this point, 100% (5/5) of the malignant samples
had a 1 score of staining, while 32% (18/57) of benign and
35% (8/23) of atypical meningiomas had the same level of
immunoreactivity. To examine distribution scores, please
refer to Table 3 and Figure 2. When the benign and the
atypical samples of meningioma were compared to the
malignant specimens with respect to the distribution of
immunoreactivity, a significant association was demon-
strated (p = 0.009) (Table 1).
The distribution of immunohistochemical scores (HIS)
was also different with respect to pathologic classifica-
tion, based on the exact Wilcoxon test with Monte Carlo
simulation (p = 0.004) (Table 1). While this demonstrates
that there was a range of IHS for the benign and the atyp-
Table 1: Comparisons of EGFR expression.
Measure Comparison performed p-value*
Staining Intensity Benign vs. Atypical vs. Malignant p = 0.002
(Benign + Atypical) vs. Malignant p < 0.001
Percentage Staining Benign vs. Atypical vs. Malignant p = 0.029
(Benign + Atypical) vs. Malignant p = 0.009
HIS Benign vs. Atypical vs. Malignant p = 0.004
(Benign + Atypical) vs. Malignant p < 0.001
* p-value based on Wilcoxon exact tests (see Methods).
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the lowest score and were statistically different from the
benign and the atypical specimens (p < 0.001) (Table 4
and Table 1). In fact, 100% of malignant meningiomas
had IHS of 0 and 1 (Table 4).
Discussion
Meningiomas are common central nervous system
tumors. Although slow growing, at times, they continue
to be a major cause of morbidity and mortality. Persistent
risk of recurrence of these tumors is a compelling reason
to seek adjuvant therapies to decrease the rates of relapse.
Recent publications report an intense search for new
molecular markers that may serve as potential therapeu-
tic targets [21-28]. EGFR has emerged as one of the novel
receptors expressed on the surface of a variety of cancers
such as colorectal, head and neck, and lung malignancies.
While its activation stimulates tumor proliferation, over-
expression of EGFR in various epithelial tumors is associ-
ated with a poor patient prognosis. The notion of its
function prompted development of inhibitors of EGFR
which have been approved for clinical use [21-28]. Our
motivation for this analysis was the fact that, to date,
there is no effective pharmacologic therapy for menin-
gioma. This study was designed to determine whether
meningiomas express EGFR, and if so, to establish a cor-
relation between the histopathologic grade of these
tumors and the degree of EGFR expression.
To our knowledge, this analysis represents the largest
series of meningiomas evaluated for EGFR expression in
the literature to date. We demonstrated that menin-
giomas express EGFR and found that there was a signifi-
cant association between the intensity of EGFR staining
and tumor grade. While the majority of samples had a
moderate level of staining intensity, the malignant tumor
grade exhibited the lowest scores. Our data demonstrate
significantly greater degree of EGFR expression in benign
and atypical meningiomas as compared to the malignant
meningiomas. With respect to percentage of immunorec-
tivity, the malignant grade of meningioma revealed lower
scores in contrast with the benign and atypical samples.
Further, malignant tumors exhibited the lowest immuno-
histochemical scores and were different from the scores
of the benign and the atypical specimens in a statistically
significant fashion. Therefore, we conclude that EGFR
expression is inversely correlated with tumor grade in
meningiomas.
Some investigators, utilizing ligand-binding tech-
niques, demonstrated a broad range of EGFR expression
in meningiomas, varying from approximately 30% to
100% [29-32]. The discrepancies in the literature regard-
ing the expression levels of EGFR in meningiomas may be
accounted for by the different techniques used in each of
these studies. In our study, we determined the expression
of EGFR in meningiomas by immunohistochemical anal-
ysis of archival tissue, and EGFR expression was detected
in 86% of all meningiomas tested. While the majority of
studies previously reported a specific EGFR immunore-
activity in the vascular endothelial cells of meningiomas
[33-36], there were others that demonstrated no such
correlation [37-40]. We presented our data with respect
to the percent of immunoreactivity (SP) in our menin-
gioma samples and found a significant association
Table 2: EGFR staining intensity of meningioma samples, n (%).
Pathology EGFR Staining Intensity
0 1 2 3
Benign 5 (13) 13 (26) 38 (48) 1 (13)
Atypical 3 (9) 6 (23) 11 (66) 3 (2)
Malignant 4 (80) 1 (20) 0 0
Table 3: Percentage of EGFR staining (immunoreactivity) of meningioma samples, n (%).
Pathology Percentage of EGFR Staining
1 (0-20%) 2 (21-40%) 3 (41-60%) 4 (61-80%) 5 (81-100%)
Benign 18 (32) 15 (26) 15 (26) 7 (12) 2 (4)
Atypical 8 (35) 6 (26) 4 (17) 3 (13) 2 (9)
Malignant 5 (100) 0 0 0 0
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EGFR and histopathologic subtype.
What does overexpression of EGFR in tumors indicate?
Carroll et al provide an explanation by examining EGFR
expression in human meningiomas by Western blot and
immunohistochemical analyses [33]. The authors specu-
late that activation of EGFR is not a result of any muta-
tions of the EGFR, but it is secondary to autocrine/
paracrine stimulation by their endogenous ligands, EGF
and TGF alpha, which are also expressed in meningiomas
and may contribute to meningothelial cell proliferation
[33]. Kong et al also supports that EGFR receptors are
regulated by autocrine mechanism [41]. An alternative
theory is that the benign histologic subtypes have a more
efficient autocrine/paracrine stimulation, which makes
them significantly different from all other types not only
in their behavior but also in their expression of EGFR
[33]. Lusis et al in a report evaluating the expression of
EGFR in 41 meningiomas identified a relatively higher
incidence of EGFR expression among incidental asymp-
tomatic meningiomas discovered at autopsy compared
with those removed during surgical treatment [42]. This
finding is consistent with the EGFR pathway of menin-
gioma growth stimulation resulting in a relatively less
aggressive tumor [42]. Smith et al reported that absence
of EGFR expression correlates with poor prognosis in
patients with meningioma [43]. Although it may be
expected that increased expression of EGFR would pro-
Figure 2 Percentage of EGFR staining by histopathological classification. Tumor sections were analyzed with respect to percent of each sample 
exhibiting staining for EGFR. The percentages of immunoreactive cells (staining percentage) were estimated by inspection and scored from 1 to 5, 1 
(< 20% of the sample exhibiting staining); 2 (21-40% of the sample exhibiting staining); 3 (41-60% of the sample exhibiting staining); 4 (61-80% of the 
sample exhibiting staining), and 5 (81-100% of the specimen stained). The findings of the immunoreactivity for EGFR on each slide were then corre-
lated with the meningioma histologic subtypes: benign, atypical, and malignant.
Table 4: Immunohistochemical Score (IHS) of meningioma samples, n (%).
Pathology Immunohistochemical Score
0 1 2 3 4 5 6 7 8 10
Benign 5 (9) 4 (7) 12 (21) 7 (12) 15 (26) 0 (0) 8 (14) 0 (0) 4 (7) 2 (4)
Atypical 3 (13) 4 (17) 3 (13) 2 (9) 2 (9) 1 (4) 2 (9) 1 (4) 3 (13) 2 (9)
Malignant 4 (80) 1 (20) 0 0 0 0 0 0 0 0
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prognosis, the opposite was true in his series. This find-
ing does not necessarily cast doubt on the theory that
EGFR is involved in the development of meningiomas, as
considerable evidence implicates this receptor in tumor
development. Instead, these data suggest that in tumors
lacking EGFR expression, other even more potent
growth-stimulatory mechanisms may exist [43].
EGFR activation increases resistance to apoptosis, pro-
motes angiogenesis, and impairs immune surveillance;
hence, intervention with an EGFR inhibitor may decrease
tumorigenic progression in patients with this disease.
While radiation therapy plays an important role in the
management of meningioma, an association between
high EGFR expression and clinical radioresistance has
been reported in patients with cancer. Correlation
between EGFR overexpression and response to radiother-
apy has been well described in human head and neck can-
cers [32]. Furthermore, overexpression of EGFR may act
as an independent prognostic factor for relapse and
recurrence of disease. Ang et al reported on patients with
squamous cell carcinomas of the head and neck
(SCCHN) as part of the correlative biomarker study,
where the overall survival (OS) and disease-free survival
(DFS) rates of patients with high EGFR-expressing
SCCHN were highly significantly lower and the local
recurrence (LR) relapse rate was significantly higher
compared with those of patients with low EGFR-express-
ing SCCHN [44]. Multivariate analysis showed that EGFR
expression was an independent determinant of OS and a
robust independent predictor of LR relapse. The data
suggest that EGFR immunohistochemistry should be
considered for selecting patients for more aggressive
combined therapies or enrollment into trials targeting
EGFR signaling pathways [44]. A phase III randomized
clinical trial evaluated the addition of cetuximab (Erbitux
TM) to high dose radiation in patients with locoregion-
ally advanced SCCHN and demonstrated a statistically
significant prolongation of OS in the combined modality
arm versus radiation alone [45,46]. EGFR overexpression
was also found to be a significant and independent prog-
nostic indicator for OS after radiation therapy in patients
with astrocytic gliomas [47]. The addition of EGFR inhib-
itors to patients receiving radiation therapy has not been
found to significantly increase the toxicity of treatment
[32,45,46]. Most toxicities associated with cetuximab in
the treatment of head and neck cancers are low grade and
cutaneous. The rationale for combination of inhibitors of
EGFR with ionizing radiation is, therefore, a potentially
attractive combination for recurrent or benign menin-
gioma.
There are now several EGFR inhibitors- Herceptin
(Trastuzumab), Erbitux (IMC-C225, cetuximab), Tarceva
(OSI-774, erlotinib), Iressa (ZD 1839), Maztuzumab
(EMD 72000) - which exhibit anti-cancer activity and are
being used in clinical practice for the tumors of breast,
colon, head and neck, lung, and others. Although the pre-
cise mechanism by which EGFR inhibitors exert their
anti-cancer effect remains unknown, compelling evi-
dence exists to further explore whether inhibitors of
EGFR will be of clinical benefit to patients with benign/
low-grade or recurrent meningioma, which represent the
vast majority of patients. The association of EGFR and
meningioma grade is a potential new avenue for thera-
peutic intervention with selective EGFR inhibitors, either
as an adjuvant treatment or in combination with radia-
tion therapy. Additional clinical studies will be needed
before inhibitors of EGFR can be incorporated into clini-
cal practice.
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